Journal
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
Volume -, Issue 1, Pages 57-66Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/hematology.2020000089
Keywords
-
Categories
Funding
- Ali McBride
- BCOP
- FASHP
- FAzPA
- University of Arizona Cancer Center
- National Institutes of Health, National Cancer Institute grant [P30CA016056]
- Roswell Park Alliance Foundation (Jacquie Hirsch Leukemia Research Fund)
Ask authors/readers for more resources
The recent advent of myriad targeted therapies for acute myeloid leukemia (AML) has led to new hope for our patients but has also introduced new challenges in managing the disease. For clinicians, the ability to treat AML in the outpatient setting with novel agents of equal or greater efficacy than 7+3 has been transformative. Despite the enthusiasm, however, the reality is that many patients are still frail and remain at risk for treatment-related complications. Translating the results of clinical trials into improved outcomes for these individuals requires an understanding of how best to manage the adverse effects of these agents. Which patients benefit most and what to watch for? When to stop therapy? Using illustrative case presentations, this review details the unique toxicities associated with each of the approved mutation-specific and nonspecific targeted drugs for AML. The goal of this review is to help clinicians determine the risk:benefit ratio in decision making for individual patients with AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available